Drugs / DSPE-DOTA-Gd Liposomal Injection
DSPE-DOTA-Gd Liposomal Injection
Trials 1
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 1 | NCT05453539 | Nov 2022 → Nov 2024 | Alzheimer disease | Alzeca Biosciences, Inc. | Terminated | No outcome recorded Stop: Enrollment |
Evidence & citations 3 cited values
Every value below carries the sentence it was read from. 1 source stands behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | DSPE-DOTA-Gd Liposomal Injection | ClinicalTrials.gov intervention name — accepted as the source's own label NCT05453539 ↗ |
| Modality | Diagnostic / imaging agent | “being developed for use in contrast-enabled MR imaging of amyloid plaques” NCT05453539 ↗ |
| Route | Intravenous | “Single dose, intravenous infusion” NCT05453539 ↗ |